Search

Your search keyword '"Bannister W"' showing total 362 results

Search Constraints

Start Over You searched for: Author "Bannister W" Remove constraint Author: "Bannister W"
362 results on '"Bannister W"'

Search Results

1. SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection

2. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection

3. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

4. SARS‐CoV‐2 testing, positivity, and factors associated with COVID‐19 among people with HIV across Europe in the multinational EuroSIDA cohort.

5. SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection

6. Factors associated with different responses to combination antiretroviral therapy in an observational cohort study of HIV-1 infected patients

8. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study

9. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

11. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

12. Studies in gastric secretion

18. Abstract P5-21-12: Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD

21. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors

22. Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies

23. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

24. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours

27. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study

28. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

29. A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study

30. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study

31. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change

32. Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe

33. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

34. Dialysis and renal transplantation in HIV-infected patients: a European survey

35. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

36. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

37. The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results

38. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients

39. Factors associated with HIV-1 virological failure in an outpatient clinic for HIV-infected people in Haiphong, Vietnam

40. Trastuzumab resistance: Bringing tailored therapy to the clinic

41. Regional changes over time in initial virological response rates to combination antiretroviral therapy across Europe.

Catalog

Books, media, physical & digital resources